Trial Profile

Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SKG-0106 (Primary) ; SKG-0106 (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions; Therapeutic Use
Sponsors Skyline Therapeutics

Most Recent Events

10 Jan 2024 Planned initiation date changed from 30 Oct 2023 to 1 Jan 2024.
10 Jan 2024 Planned End Date changed from 30 Sep 2029 to 30 Jan 2026.
10 Jan 2024 Planned primary completion date changed from 30 Nov 2025 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com